盐酸阿罗洛尔和美托洛尔对冠心病患者血压、心率、血脂和血糖的影响

Comparative study of the effect of arotinolol and metoprolol on blood pressure,heart rate,fasting plasma glucose and blood lipid in patients with coronary heart disease

目的比较盐酸阿罗洛尔和美托洛尔对于冠心病患者的血压、心率、血糖、血脂的影响。方法连续收集3个月90例冠心病病例,随机分成两组:盐酸阿罗洛尔组(A组)和美托洛尔组(B组),分别在原来治疗的基础上加用盐酸阿罗洛尔和美托洛尔。结果12周后,A组收缩压、舒张压、心率均有显著下降,降幅分别为11.1mmHg、8.9mmHg、8.3次/分;B组收缩压、心率有显著下降,降幅分别为6.7mmHg、8.2次/分。A组患者高血糖比例呈下降趋势(降幅9.1%),而B组呈上升趋势(降幅-2.4%)。A、B两组平均血脂水平(包括甘油三酯、总胆固醇、高密度脂蛋白)和平均空腹血糖无明显变化,但A组平均空腹血糖水平有下降趋势(降低1.7mmol/L)。结论盐酸阿罗洛尔是适应于冠心病患者的有效的β受体阻滞剂,尤其是对于合并高血压、糖代谢紊乱的患者,有可能成为首选用药。

Objective To compare the effect of Arotinolol and Metoprolol on blood pressure,heart rate,fasting plasma glucose and blood lipid in patients with coronary heart disease.Methods Ninety patients with coronary heart disease were enrolled consecutively.They were randomized to receive treatment with Arotinolol（A group） or Metoprolol（B group） for 12 weeks without change of other previous drugs.Results Twelve weeks later,systolic blood pressure（SBP）,diasystolic blood pressure（SBP） and heart rate（HR） were significantly reduced by 11.1 mm Hg,8.9 mm Hg,8.3 bpm respectively in patients treated with Arotinolol.And in patients treated with Metoprolol,SBP and HR were significantly reduced by 6.7 mm Hg,8.2 bpm respectively.The percent of patients with hyperglycemia in A group had descending trend（decreased by 9.1%）,but in B group had developing trend（increased by 2.4%）.There were no difference between two groups in average level of blood lipid（including TG、TC、HDL-C）and fasting plasma glucose.But it existed of the descending trend in average level of fasting plasma glucose in patients treated with Arotinolol （decreased by 1.7 mmol/L）.Conclusion Arotinolol was used effectively in treatment of coronary heart disease.It might be the β-blocker of first choice used in patients with coronary heart disease accompanied by hypertension or glycometabolism disorder.